Study of takhzyro (lanadelumab) for teens and adults with HAE in Saudi Arabia
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how well Takhzyro (lanadelumab) works for people with a specific type of hereditary angioedema (HAE) that is caused by a C1 inhibitor deficiency. It is for teenagers and adults who have already been taking Takhzyro for at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older when you started taking Takhzyro.
- You must have been diagnosed with HAE type 1 or type 2 (caused by C1 inhibitor deficiency).
- You must have been taking Takhzyro continuously for at least 6 months.
- You cannot have other forms of HAE (like type 3) or normal C1 inhibitor function.
- You must have complete medical records from when you started Takhzyro and after 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people in South Korea with hereditary angioedema. It looks at how well the drug Takhzyro works and how safe it is for teenagers and adults who are already using it or will start using it.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study is looking at how hereditary angioedema (a rare cause of severe swelling) is diagnosed and managed in Egypt. It is an observational study, meaning you won't receive any study medicine—just regular medical care while researchers collect information.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This trial lets children who already took part in a previous CSL312 study for hereditary angioedema continue receiving the medicine. It helps ensure they don't have a gap in treatment while longer-term safety and effects are monitored.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.